AI-generated · cited to primary sources · not investment advice · How we research
Navin Fluo.Intl.
Our verdict on Navin Fluo.Intl. isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
The company reported an Operating EBITDA margin of 32.5% for Q2 FY26 and 30.5% for H1 FY26, significantly exceeding the 25% floor guidance. (5 exceeded across 5 tracked commitments)
“Where we stand now in the first half, given the performance, I think we are well on track to be between 28% to 30% for the year.”
The company reported that the fluoro specialty plant (commissioned Dec 2024) contributed meaningfully in Q2 FY26, operating at optimum capacity. (2 met across 2 tracked commitments)
“Supplies for 3 new molecules to start in Q2FY26; Orders are in place”
See the full cited Management analysis of Navin Fluo.Intl.
How durable is the business?
The Specialty Chemicals segment grew 35% year-over-year, supported by optimal capacity utilization at the Dahej and Surat plants and a strong order book for the fiscal year. (5 expanding)
“Our additional HFC capacity expansion equivalent to 15,000 metric tons per annum of R32 remains on track for commissioning in quarter 3 FY27... The Chemours project is on track and expected to be completed by end June, early July.”
The HPP segment is expanding rapidly due to the successful commercialization of the R32 refrigerant project in March 2025 and firm pricing for repression gases. (5 expanding across 1 engine)
“Starting with our HPP business. Quarter 4 FY26 revenue grew 20% year-on-year at INR393 crores, driven by improved realization and volume growth... The HPP business continues to benefit from a constructive global demand-supply environment, increasing adoption of low GWP refrigerants”
See the full cited Business Model analysis of Navin Fluo.Intl.
Where does growth come from?
The CDMO business is showing accelerating momentum with a 61% YoY growth rate, significantly outpacing the company's overall revenue growth of 39%. Management indicates a robust order book for the remainder of FY26. (5 accelerating across 5 signals)
“CDMO +61% Q4 FY25 115 Q4 FY26 186”
Specialty Chemicals revenue grew 35% YoY to Rs. 219 Cr in Q1 FY26. Growth is accelerating with 3 new molecules starting supply in Q2 FY26 and a new fluoro specialty plant at Dahej contributing meaningfully this year. (4 accelerating, 1 decelerating across 5 signals, 1 leading indicator)
“Specialty Chemicals Revenues Rs. Crs 360 +39% Q4 FY25 259 Q4 FY26 360”
See the full cited Future Growth analysis of Navin Fluo.Intl.
What could break the thesis?
The risk remains STABLE as the CDMO business continues to be almost entirely export-driven, with 97% of Q1FY26 revenue coming from international markets. (4 stable, 1 easing, 1 high-severity)
“International 98% India 2%”
Regulatory risk is STABLE. The company is actively managing its 'entitlement' (legal quota) under the Kigali Montreal Protocol to maximize value across different gas blends and R32. (2 stable, 1 high-severity)
“And you should remember that quota is only going to be available as aligned with the Kigali protocol, which is '24, '25, '26 average production and 65% of your GWP or HCFC of 2009 and '10, right?”
See the full cited Risk analysis of Navin Fluo.Intl.
Read the full thesis on Navin Fluo.Intl.
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.